MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

 MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

MSD Signs a License Agreement with King’s College London & Wellcome’s Innovations to Develop Chronic Neuropathic Pain Therapies

Shots:

  • MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of dual regimen for multiple cancer indications in a P-I study
  • The collaboration will further explore the therapeutic potential of combination therapy, TJC4 with Keytruda across multiple tumors
  • I-Mab’s TJC4 is an anti-CD47 mAb, recognizes the unique epitope on CD47, thus avoid the binding to RBCs, under clinical development in the US and has received NMPA’s IND approval in China

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Plantadoce

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post